Fumeaux Thierry, Berger Claudia, Bausch Alexander, Wright Matthew, Vilimanovich Urosh, Soldatovic Ivan, Vehreschild Maria J G T
Kinarus Therapeutics AG, Technologiepark Basel, Hochbergerstrasse 60C, 4057 Basel, Switzerland.
Wemedoo AG, Sumpfstrasse 24, 6312 Steinhausen, Switzerland.
iScience. 2023 Sep 27;26(10):108038. doi: 10.1016/j.isci.2023.108038. eCollection 2023 Oct 20.
The combination of pamapimod and pioglitazone (KIN001) has a synergetic antiviral, anti-inflammatory, and antifibrotic activity, which may prevent evolution toward COVID-19-associated severe respiratory failure. In a randomized, placebo-controlled, double-blind, phase 2, multicenter trial, 128 non-critically ill hospitalized patients with confirmed COVID-19 were treated with KIN001 or a placebo for 28 days. The proportion of patients alive and free of oxygen or respiratory support at the end of the therapy was lower than anticipated but not different in the two groups (KIN001 n = 19, 29%, placebo n = 21, 33%). 85 participants had at least one adverse event, with no difference in the number and distribution of events between the two groups. The clinical trial was stopped for futility, mainly due to a lower-than-expected incidence of the primary endpoint. KIN001 was safe and well-tolerated but had no significant effect on clinical outcome.
帕马匹莫德与吡格列酮联合用药（KIN001）具有协同的抗病毒、抗炎和抗纤维化活性，这可能会阻止病情发展为与新冠病毒疾病相关的严重呼吸衰竭。在一项随机、安慰剂对照、双盲、2期、多中心试验中，128名确诊新冠病毒疾病的非危重症住院患者接受KIN001或安慰剂治疗28天。治疗结束时存活且无需吸氧或呼吸支持的患者比例低于预期，但两组之间无差异（KIN001组n = 19，29%；安慰剂组n = 21，33%）。85名参与者至少发生了一次不良事件，两组之间事件的数量和分布无差异。该临床试验因无效而停止，主要原因是主要终点的发生率低于预期。KIN001安全且耐受性良好，但对临床结局无显著影响。
